Changes to nursing home survey protocols — set to take effect April 28 — are putting a sharper focus on resident rights, ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...